20 July, 2017
Skadden represented Takeda Pharmaceutical Company Limited, a leading global pharmaceutical company based in Japan and listed on the Tokyo Stock Exchange, in connection with its US$500 million 2.45% senior notes offering due 2022. The transaction was announced on July 12 and closed on July 18.
The Skadden team included in Tokyo, partner Kenji Taneda, Asia Pacific counsel Ken Kiyota and associate Yuko Ozaki (corporate); in Palo Alto, partner Sean Shimamoto and associate Martin de Jong (tax); in New York, counsel Jeffrey Lieberman (executive compensation and benefits); and in Washington D.C., partner Eytan Fisch (sanctions).
For more information, please see Takeda Pharmaceutical's announcement here.
